What You Should Know:
- Atropos Health, leader in evidence generation for healthcare, today announced the launch of the Geneva OS (Generative Evidence Acceleration Operating System) and the ChatRWD (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation.
- The new offering will enable non technical users to generate publication grade Observational Research studies leveraging deidentified patient level real world data from the Atropos Evidence Network in a matter of minutes, saving organizations valuable time, money and staffing resources.
Exploring New Horizons with Smart Generative AI
“Evidence generation is the key to improving care and outcomes. The GENEVA OS represents a critical infrastructure layer for the healthcare ecosystem that can rapidly, accurately, and transparently convert healthcare data into personalized evidence.” said Brigham Hyde, Co-Founder and CEO of Atropos Health. “In addition our ChatRWD user application represents an evolutionary jump in the speed and user experience by which evidence can be generated. Building on the core technology behind our Green Button Informatics Consult Service, users can now generate publication grade Real World Evidence from hundreds of millions of patients’ deidentified medical records in minutes.”
Atropos Health’s GENEVA OS and ChatRWD were created for clinicians, researchers, and drug developers to address the global evidence gap and expedite decision-making. These tools can now be used alongside Atropos’ existing solutions, including the Green Button Informatics Consult Service, Atropos Evidence Network, and Atropos Evidence Library.
The launch of GENEVA OS and ChatRWD coincides with concerns in the healthcare and life sciences community about the reliability and ethics of generative AI. A study published by Stanford’s Human-Centered AI Institute, covered in Forbes and the New York Times, found that responses generated by GPT3.5 and GPT4 were often inconsistent with established literature. In contrast, ChatRWD relies on proprietary technology used in the Green Button Informatics Consult Service and utilizes real-world data from Atropos Evidence Network.
Users of Atropos Health’s GENEVA OS can anticipate faster insights and significant institutional ROI. With Atropos Health, real-world evidence-based studies can be conducted in minutes, a considerable improvement from industry averages of weeks to months. This accelerates production timelines, optimizes resources, and results in cost savings without affecting clinical outcomes.
Current Atropos Health users already have access to GENEVA OS, and the company is accepting beta users for the ChatRWD application.
